News >

FDA Grants LN-145 Breakthrough Designation for Cervical Cancer

Jason M. Broderick @jasoncology
Published: Friday, May 24, 2019

The FDA has granted a breakthrough therapy designation to the tumor-infiltrating lymphocyte (TIL) therapy LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy, according to Iovance Biotherapeutics, the manufacturer of the treatment.

Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.  J Clin Oncol. 2019;37 (suppl; abstr 2538).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication